As­traZeneca's Alex­ion to take new R&D space in biotech tow­er in New Haven

A new biotech tow­er in New Haven, Con­necti­cut, has at­tract­ed sev­er­al well-known an­chor ten­ants.

Alex­ion Phar­ma­ceu­ti­cals, bought by phar­ma gi­ant As­traZeneca for $39 bil­lion last year, is com­mit­ted to oc­cu­py­ing space at the new biotech tow­er in down­town New Haven. The 10-sto­ry, 500,000 square-foot build­ing is cur­rent­ly un­der con­struc­tion, how­ev­er, Alex­ion has al­ready com­mit­ted to tak­ing space.

Ac­cord­ing to CT In­sid­er, Alex­ion did not con­firm how much space they are oc­cu­py­ing, but a com­pa­ny spokesper­son stat­ed that the move will rep­re­sent an ex­pan­sion in Alex­ion’s re­search ca­pa­bil­i­ties, dou­bling the com­pa­ny’s lab floor space in the city.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER